{"title":"Mitochondrial DNA-Mediated Intercellular Communication via Extracellular Vesicles Under Hypoxic Stress to Drive HCC Progression.","authors":"Jiaying Fu, Qingqing Liu, Yuan Yuan, Runyuan Li, Jian Wang, Yuanxin Zhao, Xiaoyu Yan, Jing Su","doi":"10.1111/cas.70172","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy has opened new opportunities for the therapy of hepatocellular carcinoma (HCC), but is limited by the immunosuppressive microenvironment. Recent studies have reported that abnormal mitochondrial DNA (mtDNA) stress in tumor cells acts as an intercellular communication signal capable of affecting the tumor itself as well as the microenvironment, but the pathways by which mtDNA drives this process are currently unknown. In this study, we found that mtDNA is involved in hypoxia-derived EVs-mediated macrophage M2 phenotypic polarization promoting HCC progression. In vitro and in vivo experiments demonstrated that hypoxia promotes mtDNA release by enhancing mitochondrial quality control (MQC) signaling and subsequent exocytosis to macrophage via EVs. EVs carrying mtDNA activate macrophage cGAS/STING/NF-κB pathway and promote M2 phenotypic polarization. In addition, we have modified the drug by using a nanodelivery system to make it tumor-targeted and effective in inhibiting tumor growth in vivo. Taken together, our study reveals a critical role for EVs-mtDNA in the formation of the immunosuppressive microenvironment in HCC under hypoxia and provides new evidence and solutions to improve sensitivity to immunotherapy for HCC.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cas.70172","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Immunotherapy has opened new opportunities for the therapy of hepatocellular carcinoma (HCC), but is limited by the immunosuppressive microenvironment. Recent studies have reported that abnormal mitochondrial DNA (mtDNA) stress in tumor cells acts as an intercellular communication signal capable of affecting the tumor itself as well as the microenvironment, but the pathways by which mtDNA drives this process are currently unknown. In this study, we found that mtDNA is involved in hypoxia-derived EVs-mediated macrophage M2 phenotypic polarization promoting HCC progression. In vitro and in vivo experiments demonstrated that hypoxia promotes mtDNA release by enhancing mitochondrial quality control (MQC) signaling and subsequent exocytosis to macrophage via EVs. EVs carrying mtDNA activate macrophage cGAS/STING/NF-κB pathway and promote M2 phenotypic polarization. In addition, we have modified the drug by using a nanodelivery system to make it tumor-targeted and effective in inhibiting tumor growth in vivo. Taken together, our study reveals a critical role for EVs-mtDNA in the formation of the immunosuppressive microenvironment in HCC under hypoxia and provides new evidence and solutions to improve sensitivity to immunotherapy for HCC.
期刊介绍:
Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports.
Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.